Search Results

Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced that Gertjan Bartlema, Chief Executive Officer, and Peter Greaney, PhD, Chief Business Officer, will participate in meetings with investors at the Wells Fargo Virtual Private Biotech Symposium on Monday, May 6, 2024.

Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced the formation of a new Scientific Advisory Board comprising leading global experts in the field of clinical oncology.

Immodulon announces it has elected Richard Davies as Chairman of the Board and appointed Gertjan Bartlema as Chief Executive Officer and Peter Greaney as Chief Business Officer.

Immodulon, a late-stage clinical company developing a highly differentiated cancer immunotherapy that primes the patient’s own innate immune system, announces it has appointed Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer.

Immodulon, a late-stage clinical company developing a highly differentiated cancer immunotherapy that primes the patient’s own innate immune system, announces it has appointed Dr Josefine Roemmler-Zehrer, Associate Professor as Chief Medical Officer.